Human T cells engineered to express a chimeric antigen receptor (CAR) specific for folate receptor-a (FRa) have shown robust antitumor activity against epithelial cancers in vitro but not in the clinic because of their inability to persist and home to tumor in vivo. In this study, CARs were constructed containing a FRa-specific scFv (MOv19) coupled to the T-cell receptor CD3z chain signaling module alone (MOv19-z) or in combination with the CD137 (4-1BB) costimulatory motif in tandem (MOv19-BBz). Primary human T cells transduced to express conventional MOv19-z or costimulated MOv19-BBz CARs secreted various proinflammatory cytokines, and exerted cytotoxic function when cocultured with FRa þ tumor cells in vitro. However, only transfer of human T cells expressing the costimulated MOv19-BBz CAR mediated tumor regression in immunodeficient mice bearing large, established FRa þ human cancer. MOv19-BBz CAR T-cell infusion mediated tumor regression in models of metastatic intraperitoneal, subcutaneous, and lung-involved human ovarian cancer. Importantly, tumor response was associated with the selective survival and tumor localization of human T cells in vivo and was only observed in mice receiving costimulated MOv19-BBz CAR T cells. T-cell persistence and antitumor activity were primarily antigen-driven; however, antigen-independent CD137 signaling by CAR improved T-cell persistence but not antitumor activity in vivo. Our results show that anti-FRa CAR outfitted with CD137 costimulatory signaling in tandem overcome issues of T-cell persistence and tumor localization that limit the conventional FRa T-cell targeting strategy to provide potent antitumor activity in vivo. Cancer Res; 71(13);
Introduction
Immune targeting of tumor antigens that are overexpressed by cancer cells in numerous cancer types with limited expression in normal tissues holds significant promise for widespread clinical application. Folate receptor-a (FRa) is a glycosylphosphatidylinositol-anchored protein that is overexpressed on the surface of cancer cells in a spectrum of epithelial malignancies, including ovarian, breast, renal, colorectal, lung, and other solid cancers but limited in normal tissues (1) (2) (3) (4) (5) (6) (7) (8) . FRa overexpression is associated with highgrade tumor progression, poor prognosis in ovarian cancer (9) , and poor survival in breast cancer (10) , and therefore represents an attractive candidate for targeted biological therapy of epithelial-derived cancers, particularly for epithelial ovarian carcinomas (EOC) where approximately 90% of cancers express FRa.
Chimeric antigen receptors (CAR) or "T-bodies" couple the high affinity binding of antibodies with the signaling domains of the T-cell receptor (TCR) CD3z chain for specified triggering of T-cell activation similar to the endogenous TCR (11) . Despite promising results in neuroblastoma (12, 13) and lymphoma (14, 15) , transfer of T cells genetically redirected with CAR to FRa in a phase I clinical trial for the treatment of metastatic ovarian cancer did not induce tumor regression due to the poor persistence of the gene-modified T cells in vivo, a lack of T-cell localization to tumor, and the induction of an undefined T-cell inhibitory factor in the serum of several patients (16) . Persistence of tumor antigen-specific T cells after adoptive transfer correlates with tumor regression in patients with advanced metastatic cancer (17) , where transferred T cells can localize to regressing lesions (18) . Transferred T cells persisting in the blood of responding patients express high levels of costimulatory receptors (19, 20) and response to therapy is associated with the transfer of high numbers of T cells expressing costimulatory receptors (21) , suggesting that provision of costimulatory signals is necessary to facilitate improved T-cell survival and antitumor response in vivo. The addition of costimulatory domains, including the intracellular domain of CD28, and TNF receptor family members, CD134 (OX-40) and CD137 (4-1BB) into CARs can significantly augment the ability of these receptors to stimulate cytokine secretion and enhance antitumor efficacy in preclinical animal models of solid tumors and leukemia that lack cognate costimulatory ligands (13, (22) (23) (24) , and thus rationalizes the incorporation of costimulatory modules in the creation of anti-FRa CAR therapy.
Here, we addressed the issue of limited FRa-specific T-cell persistence and tumor activity in vivo through the introduction of the CD137 costimulatory signaling domain into a FRaspecific CAR and studied the role of CD137 signaling in FRadirected CAR T-cell therapy of human cancer. Compared with "first-generation" CAR that provide CD3z signaling to T cells but lack cis costimulatory signaling capacity, T cells expressing FRa-specific CAR with a CD137 signaling domain in tandem showed minimally improved antitumor activity in vitro, but markedly superior tumor regression capacity in established human ovarian cancer xenograft models, which was associated with enhanced T-cell persistence and tumor localization in vivo. Tumor regression and T-cell persistence were both attainable by various routes of T-cell infusion, and intravenous (i.v.) cell infusion mediates the regression of human cancer in xenograft models of advanced intraperitoneal (i.p.), subcutaneous (s.c.), and lung-involved metastatic disease. T-cell persistence and tumor activity in vivo were largely antigen-driven; however, provision of CD137 signaling in the absence of specific antigen recognition by CAR could improve T-cell persistence but not antitumor activity in vivo. Incorporation of the CD137 signaling domain in FRa-specific CARs thus overcomes the limitation of past CAR approaches by improving the persistence of transferred T cells in vivo, and bolstering their accumulation in tumor and antitumor potency.
Materials and Methods

Anti-FRa chimeric immune receptor construction
The MOv19 scFv-based (2, 25, 26) chimeric immune receptor was constructed by using pCLPS lentiviral vector backbone constructs previously described (22) . CAR construction and lentivirus production are detailed in Supplementary Materials and Methods.
Human T cells
Primary human CD4 þ and CD8 þ T cells, which were purchased from the Human Immunology Core at University of Pennsylvania, were isolated from healthy volunteer donors following leukapheresis by negative selection. All specimens were collected under a protocol approved by a University Institutional Review Board, and written informed consent was obtained from each donor. T cells were cultured in complete media (RPMI 1640 supplemented with 10% heat inactivated FBS, 100 U/mL penicillin, 100 mg/mL streptomycin sulfate, 10 mmol/L HEPES), and stimulated with anti-CD3 and anti-CD28 monoclonal antibodies (mAb)-coated beads (Invitrogen) as described (27) . Twelve to twenty-four hours after activation, T cells were transduced with lentiviral vectors at multiplicity of infection of approximately 5 to 10. CD4 þ and CD8 þ T cells used for in vivo experiments were mixed at 1:1 ratio, activated, and transduced. Human recombinant interleukin-2 (IL-2; Novartis) was added every other day to a 50 IU/mL final concentration and a cell density of 0.5 Â 10 6 to 1 Â 10 6 cells/ mL was maintained. Once T cells seemed to rest down, as determined by both decreased growth kinetics and cell sizing by using the Multisizer 3 Coulter Counter (Beckman Coulter), engineered T-cell cultures were adjusted to equalize the frequency of transgene expressing cells prior to functional assays.
Functional assays
Cytokine release assays were carried out by an IFN-g ELISA Kit (Biolegend) or by Cytometric Bead Array, according to manufacturer's instructions (BD Biosciences) as described in Supplementary Materials and Methods. Cell-based bioluminescence and 51 Cr release assays of cytolysis were carried out as previously described (28, 29) .
Xenograft model of ovarian cancer
Mouse studies were carried out as previously described (22, 30) with modifications detailed in Supplementary Materials and Methods.
Immunohistochemistry
Fresh frozen tumor samples were sectioned for immunohistochemical analysis as described in Supplementary Materials and Methods.
Statistical analysis
Statistical analysis was carried out by 2-way repeated measures ANOVA for the tumor burden (tumor volume, photon counts). Student's t test was used to evaluate differences in absolute number of transferred T cells, cytokine secretion, and specific cytolysis. Kaplan-Meier survival curves were compared by using the log-rank test. GraphPad Prism 4.0 (GraphPad Software) was used for the statistical calculations. P < 0.05 was considered significant.
Results
CAR construction
The mouse anti-human FRa-specific scFv MOv19 was selected on the basis of its high binding affinity for FRa (10 8 - 10 9 M À1 ; refs. 2, 25, 26) . FRa CAR constructs were comprised of the MOv19 scFv linked to a CD8a hinge and transmembrane region, followed by a CD3z signaling moiety alone (MOv19-z) or in tandem with the CD137 intracellular signaling motif (MOv19-BBz; Fig. 1A) . A signaling deficient FRa-specific CAR containing a truncated CD3z intracellular domain (MOv19-Dz) was designed to assess the contribution of CD3z signaling. An anti-CD19 CAR containing CD3z and CD137 signaling motifs in tandem (anti-CD19-BBz) was used as an antigen specificity control (30) . CAR constructs were subcloned into the pCLPS lentiviral vector where transgene expression is driven off the cytomegalovirus promoter. Using gene transfer technology established for clinical application, lentiviral vectors efficiently transduced primary human T cells to express the anti-FRa CAR (Fig. 1B) . T-cell transduction efficiency, as assessed by flow cytometry, was equilibrated for all constructs at approximately 50% in all assays.
Primary human FRa CAR T cells exert antigen-specific function in vitro Because ovarian cancer frequently express FRa (2), a panel of established human ovarian cancer cell lines that express surface FRa at varying levels (SKOV3, A1847, and OVCAR3) was selected for assays (Fig. 1C) . Two ovarian cancer lines, C30 and PEO-1, were negative for FRa. Transduced T cells expressing MOv19-BBz or MOv19-z CARs recognized FRa þ tumor lines and secreted high levels of IFN-g, but not when stimulated with FRa À lines (Fig. 1D ).
FRa-specific CAR T cells also secreted high levels of IL-2 and TNF-a when stimulated with FRa þ cancer cells and low but detectable levels of IL-4 and IL-10 ( Supplementary Fig. S1 ). MOv19 CARs functioned in both primary human CD4 þ and CD8 þ T cells. In all cases, MOv19-BBz T cells secreted more IFN-g than MOv19-z T cells after specific stimulation. CD19-BBz CAR did not produce IFN-g, except when coincubated with K562 cells engineered to express surface CD19 antigen, and human T cells expressing MOv19-Dz CAR did not secrete cytokine when stimulated with FRa þ cancer cells (Fig. 1D) , showing that antigen specificity and CD3z signaling are required for CAR activity in T cells. 
anti-CD19-BBζ Fig. 2A and B) . Tumor growth was modestly delayed in mice receiving MOv19-z T cells (P ¼ 0.027), compared with all 3 control groups at the latest evaluated time point (38 days after first T-cell dose). In contrast, mice receiving i.t. injection of MOv19-BBz T cells experienced rapid tumor regression, which was significantly better than MOv19-z T cells (P < 0.001), indicating that incorporation of CD137 signals enhances overall antitumor activity in vivo. Tumor-bearing mice treated with MOv19-BBz-transduced T cells delivered via i.v., i.p. injection, or i.t. routes experienced tumor regression (Fig. 2C) . Following i.v. or i.p. infusion of MOv19-BBz T cells, antitumor activity was again observed, though delayed in regression by approximately 7 days relative to i.t. delivery, indicating that although local injection is optimal, systemically infused CAR T cells can marginalize upon adoptive transfer to mediate potent antitumor effects in vivo.
Persistence of primary human FRa CAR T cells in vivo is increased by 4-1BB signals
The persistence of transferred tumor-reactive T cells following adoptive T-cell therapy is highly correlated with tumor regression (17) . In the experiments described earlier, peripheral blood was collected from tumor-bearing mice 3 weeks after the last T-cell dose and quantified for persistent human CD4 þ and CD8 þ T cells (Fig. 2D ). CD4 þ and CD8 þ T-cell counts were highest in mice receiving MOv19-BBz CAR T cells, whether delivered by i.t., i.p., or i.v. routes of administration, compared with gfp, MOv19-Dz, and MOv19-z treatment groups. Notably, human T-cell counts in mice receiving MOv19-BBz CAR T cells by i.v. injection was significantly higher than those in the parallel MOv19-z CAR group (P < 0.01), indicating a role for CD137 in T-cell survival in vivo.
There was no significant difference in level of T-cell persistence among mice receiving MOv19-BBz CAR T cells by i.v., i.t., or i.p. injection (P ¼ 0.2), despite a trend toward less cells in the i.v. injection group. Total T-cell counts in the MOv19-z treatment group was statistically similar to other control groups including mice receiving saline in the absence of human T-cell injection (Supplementary Fig. S3 ; P > 0.05), suggesting that antigen specificity alone is not sufficient for T-cell maintenance in vivo. This was primarily attributed to poor CD4 þ T-cell persistence because circulating MOv19-z CAR CD8 þ T cells persisted at greater numbers than MOv19-Dz CAR (P ¼ 0.026) or gfp (P ¼ 0.013) cells. Four weeks after last MOv19-BBz CAR T-cell dose, the absolute number of human T cells persisting in the blood was inversely correlated with tumor burden of each group (Supplementary Fig. S3 ; r ¼ -0.78). Tumor BLI results were consistent with the size of resected residual tumors (Supplementary Fig. S4 ). Mechanistically, enhanced persistence of MOv19-BBz CAR T cells, compared with MOv19-z, seemed to be attributed in part to an increased upregulation of antiapoptotic Bcl-X L protein expression after antigen stimulation (Supplementary Fig. S3 ). Thus, tumor regression was associated with the stable persistence of engineered human T cells in vivo and supported by provision of CD137 costimulation.
Tumor regression and T-cell persistence are antigendriven in vivo
To determine whether MOv19-BBz CAR antitumor activity is antigen-specific, a comparative study was conducted with an anti-CD19-specific CAR also containing the CD137 signaling domain (30) . NSG mice with established s.c. SKOV3 fLuc þ tumor receiving 2 i.t. T-cell injections experienced rapid tumor regression, whereas tumor grew progressively in mice treated with T cells expressing gfp or CD19-BBz CAR (Fig. 3A) , excluding alloreactivity as a mechanism of tumor regression. Mice receiving MOv19-BBz T cells had significantly higher human CD4 þ and CD8 þ T cell counts than mice in anti-CD19 CAR or gfp groups (Fig 3B; P ¼ 0.009), indicating that tumor antigen recognition drives the survival of the adoptively transferred T cells in vivo. Interestingly, T-cell persistence was reproducibly higher in mice receiving anti-CD19-BBz CAR T cells than gfp T cells (P ¼ 0.012), suggesting that persistence of CAR T cells can be promoted in part through a CD137-driven process that does not require scFv engagement with antigen. Nevertheless, there was no statistical difference in tumor control between anti-CD19-BBz CAR and gfp groups (P ¼ 0.065) even at the latest time point studied (day 73), showing that persistence in the absence of antigen specificity is insufficient to mediate tumor response. In this line, CAR expressing T-cell frequency in the blood of tumor-bearing mice administered MOv19-BBz T cells was higher than that observed in mice receiving CD19-BBz CAR T cells, though not at statistical significance ( Fig. 3C ; P ¼ 0.08). However, coupled with increased T-cell counts, the total number of circulating CAR þ T cells persisting 1 month after infusion were significantly higher in mice receiving MOv19-BBz T cells (76 AE 13 cells/mL; P ¼ 0.013); mice in CD19-BBz CAR and gfp groups had little to no detectable persistence of CAR þ T cells with counts of 12 AE 4 cells/mL and 0 AE 0 cells/ml, respectively (Fig. 3D) . Consistent with the increased persistence of MOv19-BBz T cells in the blood of treated animals, immunohistochemical analysis revealed robust accumulation of human CD3 þ T cells in regressing SKOV3 lesions 6 weeks after i.v.
T-cell administration (Fig. 4) . Few CD3 þ T cells were detected in tumors resected at the same time from mice that received anti-CD19-BBz CAR or gfp-transduced T cells.
Tumor regression in the metastatic disease setting
Advanced ovarian cancer is a disease usually confined to the peritoneal cavity with occasional metastatic spread to the pleural compartment. A xenogeneic model of advanced i.p. metastatic cancer was established to evaluate the functional activity of FRa-specific T cells against tumor localized to a more physiologically relevant compartment. NSG mice that were inoculated i.p. with SKOV3 fLuc þ cells efficiently developed peritoneal carcinomatosis which was readily evident 30 days p.i., when MOv19-BBz or control anti-CD19-BBz CAR T-cell therapy was administered (Fig. 5A) . Within 3 weeks of T-cell transfer, all mice that received control anti-CD19-BBz CAR T cells developed distended abdomens, marked bloody ascites of approximately 5 to 8 mL volume and multiple nodular peritoneal tumors, and had to be euthanized due to tumor-associated, abdominal distention ( Fig. 5B and C) . By comparison, mice treated with MOv19-BBz CAR T cells did not develop distended abdomens or ascites, and exhibited a profound enhancement in tumor-related survival (P ¼ 0.0002) with no cases of tumor-related mortality in the MOv19-BBz CAR group (Fig. 5C ). At the time of euthanasia of mice treated with MOv19-BBz, tumor burden was minimal to none, but mice required euthanizing due to signs of distress compatible with GVHD that develops in NSG mice following xenogeneic transfer of activated human lymphocytes (32) . Still, median survival times of 52 days after last T-cell infusion by i.v. injection and 68 days by the i.p. route were observed in mice treated with MOv19-BBz CAR, compared with 9 and 12 days in the anti-CD19-BBz CAR T-cell groups, respectively (MOv19-BBz i.p. vs. anti-CD19-BBz i.p., P ¼ 0.0023; MOv19-BBz i.v. vs. anti-CD19-BBz i.v., P ¼ 0.0025; Fig. 5D ). Two months after treatment with MOv19-BBz CAR cells via i.p. or i.v. routes, 60% (3 of 5) and 40% (2 of 5) of tumor-inoculated mice remained alive, respectively. Occasionally, ovarian cancer patients develop lung metastases and pleural ascites formation requiring thoracentesis or other supportive management procedures during disease progression (33) . A model of metastatic ovarian cancer of lung was generated by inoculation of NSG mice with SKOV3 fLuc þ cells via tail-vein injection resulting in progressive lung metastases in 100% of mice 3 days p.i. (Fig. 6) . Two i.v. injections of MOv19-BBz T cells resulted in rapid regression of lung metastasis in all treated animals 14 days p.i. and 80% (4 of 5) of mice had no evidence of recurrence after 1 month. By contrast, disease progression occurred in all mice receiving anti-CD19-BBz T cells.
Discussion
CARs combine the high affinity and specificity of antigenspecific antibody, which binds cell surface determinants in a non-MHC-restricted manner, with the potent effector functions of T lymphocytes (11) . Genetically retargeting of primary human lymphocytes with CARs recognizing tumor-associated antigens offers a robust and rapid avenue toward the generation of tumor-reactive T cells for therapy. To date, CAR-based therapy has shown promising but often limited clinical activity, despite the reproducible demonstration of strong effector activity in vitro (12) (13) (14) (15) (16) . Effective adoptive T-cell therapy not only requires antitumor activity, but also in vivo expansion and persistence of the infused tumor-reactive T cells (17) . In our study, we have addressed the central issue of limited CAR T-cell persistence and tumor activity in vivo (16) through the introduction of the CD137 (4-1BB) costimulatory signaling domain into a Mov19 scFv-based CAR.
CD137 is a TNF receptor family member that plays an important role in T-cell proliferation and survival, particularly for T cells within the memory T-cell pool (34) (35) (36) . We selected CD137 on the basis of its demonstrated capacity to support of CD8 T-cell expansion (36) , and upregulate important antiapoptotic protein Bcl-X L expression (37) that adoptive transfer of tumor-specific T cells costimulated ex vivo with 4-1BBL supports persistence and antitumor activity in vivo (38) . This work builds upon our previous study which showed high costimulatory receptor expression on tumor antigen-specific T cells persisting in the circulation in patients responding to adoptive immunotherapy (19) , and correlations between costimulatory receptor expression on transferred T cells and tumor regression (20;21) . Like the "firstgeneration" Mov19-z CAR expressing CD3z signaling alone, T cells engineered to express a "second-generation" Mov19-BBz CAR containing CD3z signaling and a CD137 signaling domain in tandem preferentially secrete high levels of Th1 cytokines including IFN-g, TNF-a, and IL-2 upon tumor encounter and exert strong antitumor activity in vitro. Here, IFN-g cytokine production levels were generally associated with the level of FRa expressed by tumor cell targets, and cytolysis of tumor cells by Mov19-z CAR and Mov19-BBz CAR T cells was efficient even at a 3:1 effector to target cell (E/T) ratio in vitro. In all in vitro antitumor assays, engineered T cells expressing Mov19-BBz CAR outperformed Mov19-z CAR T cells, albeit not always to the level of statistical significance. Interestingly, the single exception was in the level of Th2 cytokine secretion induced by tumor stimulation, where FRa engagement by Mov19-z CAR T cells induced greater IL-4 and IL-10 production, suggesting that combined CD3z and CD137 signaling enforces a Th1 skewed response.
The dichotomy between first-and second-generation CAR vectors was most evident in in vivo studies where CD137 (18, 39) , tumor response was associated with enhanced T-cell persistence and tumor localization of Mov19-BBz CAR T cells in vivo, which seemed to be attributed in part to upregulated expression of Bcl-X L following stimulation with tumor. Tumor regression was antigen-specific, as transfer of anti-CD19-BBz T cells had no impact on tumor progression. Tumor regression and T-cell persistence were attainable via systemic or local T-cell delivery, showing the capacity of transferred T cells to circulate, home to tumor and perform antitumor functions. Although i.v. injections are favorable in clinical application due to the ease of administration and effective in our model, our data suggest that local administration of T cells may provide optimal therapeutic effect, which may be in part due to increased T-cell trafficking to tumor and provision of favorable E/T ratios. However, such delivery may not be applicable for tumors with multiple gross metastatic sites or micrometastases.
Although Mov19-BBz and anti-CD19-BBz T cells could be detected in the peripheral blood 3 weeks after T-cell infusion, (40) . In a previous study, transferred TCR transgenic T cells migrated indiscriminately early after adoptive transfer but experienced antigen-dependent activation exclusively in antigen-positive tumor resulting in tumor destruction (41) . Transfer of chemokine receptor expressing CAR T cells can enforce preferential migration to tumor sites to boost antitumor activity in vivo (42) . Our results support the hypothesis that T-cell persistence, localization, and tumor activity in vivo are largely antigen-dependent, likely linked, processes. Notably, the use of anti-CD19-BBz T cells as specificity control in our assays, however, shows that provision of CD137 signaling by CAR permitted improved T-cell persistence but not antitumor activity in vivo through a mechanism that is independent of scFv engagement with antigen, suggestive of low-level constitutive activity by the CD137 module, consistent with previous data (30) . In this scenario, it remains possible that persistence of nonspecific CD137-costimulated human T cells was driven by low-level TCR recognition of xenoantigens in mice combined with constitutive CD137 signaling by CAR, as shown by the occurrence of graft-versus-host manifestations, which is an inherent limitation of the xenogeneic NSG mouse model used. T-cell-based targeting of FRa has been tested in patients with advanced ovarian cancer with promising results. In an earlier clinical study, retargeted T cells were generated for therapy by loading preactivated T cells with a bispecific mouse mAb OC/TR, directed to the CD3 molecule on T lymphocytes and to FRa on EOC cells (43) . Administration of FRa-redirected T cells to women with minimal residual ovarian cancer resulted in antitumor responses in 27% of patients with mild to moderate immunotherapy-related toxicities; however, therapy was limited by the inability to generate stable anti-FRaspecific T-cell memory and the induction of human antimouse antibodies against the bispecific mAb in approximately 90% of treated patients (44) . In a phase I study of anti-FRa CAR therapy for cancer, Kershaw and colleagues (16) transferred T cells that were retargeted to FRa by a first-generation MOv18 scFv-based CAR to immunocompetent patients with advanced ovarian cancer. The parental MOv18 antibody has a similar affinity for FRa (10 8 À10 9 M À1 ) as MOv19 used in our CAR construct (2, 26) though the relative affinities of their scFv products in CARs is not known. MOv18 and MOv19 also bind non-cross-reactive epitopes (2), which may influence their relative ability to access surface antigen. Therapy using MOv18-z CAR was safe and feasible; however, no patient experienced a tumor response which was attributed to a lack of transferred T-cells persistence after infusion, poor tumor localization, and the development of a serum inhibitory factor that reduced CAR T-cell activity in in vivo study (16) . Our studies, combined with recent clinical strategies, address these issues. Similar to the study of Kershaw and colleagues (16) , first-generation MOv19-z CAR, which redirected T-cell cytotoxicity in vitro, only delayed tumor progression in vivo and CARs did not persist long-term in vivo. We show that tumor response and T-cell persistence can be evoked by provision of CD137 costimulatory signals to anti-FRa CAR T cells, which is facilitated principally by engagement of their CAR with tumor antigen. Moreover, transfer of MOv19-BBz T cells leads to increased accumulation of human T cells in regressing ovarian cancer lesions. Although the mouse antihuman MOv19 scFv used in the construction of the MOv19-BBz CAR is likely to elicit anti-mouse humoral responses in immunocompetent recipients, as seen in past CAR studies and trials using MOv18 scFv (16, 44, 45) , nonmyeloablative immunosuppressive preconditioning can disable host endogenous immunity to promote the in vivo persistence of T cells expressing CARs and TCRs of mouse origin, facilitating tumor regression (14, 46, 47) . The use of immunodeficient NSG mice models T-cell transfer in the setting of host lymphodepletion, albeit in the absence of human derivatives and endogenous immune reconstitution. Still, the use of fully human anti-FRa scFv candidates for the next generation of CAR-redirected therapy is worthy of investigation (26, 48) . Our preclinical results support the notion that incorporation of the CD137 signaling domain in FRa-specific CARs overcomes the limitations of past CAR approaches by improving the persistence of transferred T cells in vivo, thereby increasing their retention in tumor and bolstering antitumor potency. Careful considerations must be made when targeting of self/tumor antigens with CARs or exogenous TCRs, which hold the potential for mediating serious adverse events (47, 49) ; however, FRa, which is present on normal tissues, is localized primarily to the apical surfaces of polarized epithelia, where it may be inaccessible to parenterally administered folate conjugates and redirected T cells (50) . Our results provide the rationale for the clinical investigation of MOv19-BBz CAR T-cell therapy in combination with lymphodepleting preconditioning (High) (Low) regimens for the treatment of a wide spectrum of FRaexpressing epithelial malignancies.
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